Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AVE-3085 is a potent enhancer of endothelial nitric oxide synthase, and used for cardiovascular disease treatment.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 892 | 5日内发货 | ||
5 mg | ¥ 1,490 | 5日内发货 | ||
25 mg | ¥ 5,900 | 6-8周 | ||
50 mg | ¥ 7,670 | 6-8周 | ||
100 mg | ¥ 12,200 | 6-8周 |
产品描述 | AVE-3085 is a potent enhancer of endothelial nitric oxide synthase, and used for cardiovascular disease treatment. |
体外活性 | AVE3085 also prevents the elevation of O2.? and ONOO? levels in coronary arteries exposed to ADMA[2]. AVE3085 (10 μM) markedly increases ACh-induced relaxations in SHR aortae without affecting those in WKY aortae. And it also increases the eNOS expression in WKY aortae[3]. Pre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOSSer1177, and loares the level of p-eNOSThr495 and nitrotyrosine. NO release in response to bradykinin is significantly reduced by ADMA and such reduction is restored by AVE3085. |
体内活性 | AVE 3085 treatment attenuates the increase in the expression of Smad2 mRNA and it also attenuates the collagen volume fraction levels compared to the vehicle-treated mice. AVE3085 treatment for 4 weeks increases levels of p-eNOS and eNOS in SHR aortae without affecting levels of eNOS and p-eNOS in WKY aortae[3]. AVE 3085 (10 mg/kg/day, p.o.) treatment prevents the increases in the left ventricular weight, left ventricular weight/body weight ratio, mean myocyte diameter, and the expression of the hypertrophic markers ANP and β-MHC compared to the vehicle-treated mice. AVE3085 (10 mg/kg, p.o.) significantly improves ACh-induced endothelium-dependent relaxations in the aortae of SHRs, and reduces systolic blood pressure in SHRs. In the AVE 3085-treated mice, the EFs, FSs, mitral E velocity, E/A ratio and LVDds are significantly improved compared to the vehicle-treated mice. Furthermore, the levels of the eNOS protein expression are significantly up-regulated in the AVE 3085 group than in the vehicle-treated AB group[1]. |
别名 | AVE-3085 |
分子量 | 317.29 |
分子式 | C17H13F2NO3 |
CAS No. | 450348-85-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AVE3085 450348-85-3 Others AVE-3085 AVE 3085 Inhibitor inhibitor inhibit